Search results
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
CNBC· 2 weeks agoModerna on Thursday posted a narrower-than-expected loss for the first quarter as the company's...
Moderna beats estimates in Q1 2024, targets RSV vaccine launch in fall By Investing.com
Investing.com· 2 weeks agoModerna Inc. (NASDAQ:MRNA) reported first-quarter earnings and revenue that came ahead of analyst...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune via Yahoo Finance· 2 weeks agoThose products could range from RSV vaccines to individualized cancer treatments, which will help...
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Market Watch· 2 weeks agoModerna Inc. on Thursday reported a narrower-than-expected first-quarter loss as the COVID vaccine...
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 2 weeks agoSales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter...
Moderna reports $1.2bn net loss in Q1 2024
Pharmaceutical Technology via Yahoo Finance· 2 weeks agoThis downturn aligns with the expected transition to a seasonal market for Covid-19 vaccines. During Q1 2023, Moderna received revenue from doses...
Moderna (MRNA) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 2 weeks agoYou can access the press release issued this morning as well as the slides that we'll be reviewing by going to the investor section of our website. On...
Moderna stock surges 15% after it beat earnings expectations despite plummeting COVID vaccine sales
Quartz· 2 weeks agoModerna stock soared on Thursday after its first-quarter earnings report sailed past Wall Street’s...
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga· 2 weeks agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co...
Moderna’s mRNA dreams meet reality with first post-COVID shot - The Boston Globe
The Boston Globe· 5 days agoModerna’s stock dropped 45 percent last year, making it the worst-performing large biotech in the...
